【百时美施贵宝(BMY.US)新药需求强劲!Q2营收超预期,大幅上调2026全年业绩指引】智通财经APP获悉,由于在新款心脏病和癌症药物的领衔下,百时美施贵宝(BMY.US)旗下大部分药物组合的第二季度需求超出了华尔街预期,该公司提高了 2026 年全年的销售额和利润展望。财报显示,该公司Q2营收达 129.7 亿美元,同比增长 5.7%,超出预期 12.3 亿美元;调整后每股收益为2.04美元,超出预期0.44美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.